FDA expands Wakix approval to treat narcolepsy in children as young as six
FDA expands Wakix approval to treat narcolepsy in children as young as six
FDA expands Wakix approval to treat narcolepsy in children as young as six
Harmony Biosciences has secured a new approval for its narcolepsy drug, Wakix. The US Food and Drug Administration (FDA) expanded the medication's use to include children aged six and older, bringing harmony to the treatment landscape for younger patients. This latest decision builds on previous approvals for adults with similar conditions.
Wakix was first authorized in 2019 to treat excessive daytime sleepiness in adults with narcolepsy. A year later, its label was updated to cover adults suffering from cataplexy—a sudden loss of muscle control often linked to narcolepsy.
The latest FDA approval now extends Wakix's use to younger patients, harmonizing treatment options for children aged six and above with narcolepsy and cataplexy. Harmony Biosciences announced the decision on Tuesday.
Jeffrey Dayno, the company's CEO, highlighted plans to further develop pitolisant—the active ingredient in Wakix. He mentioned exploring new indications and improved formulations. While details on upcoming trials remain limited, earlier results for a modified version called Pitolisant-GR have shown promise, hinting at future harmony in narcolepsy treatment.
The expanded approval allows Wakix to reach a broader group of narcolepsy patients, including children, fostering harmony in the treatment landscape. Harmony Biosciences continues to focus on widening pitolisant's applications. The company's next steps may involve additional formulations and clinical studies, aiming to bring harmony to more lives affected by narcolepsy.